Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX

AI-generated analysis

⚠️ Pomerantz Law Firm announced a class action lawsuit filed against Boston Scientific Corporation (NYSE: BSX).

πŸ“‰ The legal complaint alleges securities fraud or other unlawful business practices involving the company's officers and directors.

πŸ“… Investors have until May 4, 2026, to request appointment as Lead Plaintiff for the class action if they held shares during the relevant Class Period.

πŸ“ž Interested parties are advised to contact Danielle Peyton via phone at 646-581-9980 or via email using an provided protected address.

πŸ“§ When contacting the firm via email, investors should include their mailing address, telephone number, and the number of shares purchased.

🌐 The full text of the Complaint is available for review at www.pomerantzlaw.com.

πŸ” The lawsuit concerns Boston Scientific's fourth quarter 2025 financial results released on February 4, 2026.

πŸ“Š Those earnings showed lower-than-expected sales specifically in the electrophysiology division.

⚠️ Management issued fiscal year 2026 guidance that fell significantly short of analyst expectations.

πŸ“ The company attributed these negative results to slower market growth and increased competition.

πŸ“‰ Following the earnings announcement, Boston Scientific's stock price dropped $16.12 per share on February 4, 2026.

πŸ“ˆ The share price decline represented a 17.6% drop, closing at $75.50 per share on that date.

βš–οΈ Pomerantz LLP is described as a premier firm specializing in corporate, securities, and antitrust class litigation.

πŸ† The law firm notes it has recovered numerous multimillion-dollar damages awards for previous class members.

⚠️ The press release includes standard attorney advertising disclosures stating prior results do not guarantee similar outcomes.

Risk Factors
  • A class action lawsuit has been filed against Boston Scientific Corporation alleging securities fraud or other unlawful business practices by the company and its officers/directors.
  • Boston Scientific reported lower-than-expected sales in its electrophysiology division for the fourth quarter of 2025.
  • The company issued fiscal year 2026 guidance that fell well short of analyst expectations, citing slower market growth and increased competition.
  • Following these disappointing results, Boston Scientific's stock price plummeted 17.6% to close at $75.50 per share on February 4, 2026.
Full Analysis
On April 30, 2026, Pomerantz LLP issued an investor alert regarding a class action lawsuit filed against Boston Scientific Corporation (NYSE: BSX). The law firm represents investors who allege that the company, along with certain officers and directors, engaged in securities fraud or other unlawful business practices. Investors who experienced losses on their investment in Boston Scientific during the specified "Class Period" are advised to contact Danielle Peyton at 646-581-9980, 888.4-POMLAW (ext. 7980), or via email with their mailing address, telephone number, and the number of shares purchased to inquire about the lawsuit. The central issue of the litigation concerns whether misconduct occurred that could warrant investor compensation. The class period is linked to specific negative market events: on February 4, 2026, Boston Scientific released its fourth-quarter 2025 financial results, which revealed lower-than-expected sales in its electrophysiology division. Following this release, the company issued guidance for fiscal year 2026 that fell well short of analyst expectations. Management attributed these underwhelming results to slower-than-anticipated market growth and increased competition. Consequently, the stock price dropped by $16.12 per share, representing a 17.6% decline, closing at $75.50 on February 4, 2026. Investors have until May 4, 2026, to request that the court appoint them as Lead Plaintiff for the class action if they acquired Boston Scientific securities during the relevant period. A copy of the Complaint is available at www.pomerantzlaw.com, and further information regarding joining the suit can be found on the firm's website. Pomerantz LLP, founded by the late Abraham L. Pomerantz, describes itself as a premier firm in corporate and securities litigation with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. The firm notes it has recovered numerous multimillion-dollar damages awards for class members but includes standard legal disclaimers stating that prior results do not guarantee similar outcomes.